Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019
October 08 2019 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it
will report its third quarter 2019 financial results on Tuesday,
October 29, 2019 after the close of financial markets. Following
the announcement, company management will host a conference call
and webcast discussion of the results and provide a general
corporate update. Access to the event can be obtained as
follows:
LIVE access on Tuesday, October 29, 2019 1:30 p.m. Pacific Time
/ 4:30 p.m. Eastern Time
- Telephone 800-353-6461 (domestic) or +1 334-323-0501
(international); conference ID 9057897
- Webcast with slides available at www.seattlegenetics.com in the
Investors section
REPLAY access
- Telephone replay will be available beginning at approximately
4:30 p.m. PT on Tuesday, October 29, 2019 through 5:00 p.m. PT on
Friday, November 1, 2019 by calling 888-203-1112 (domestic) or +1
719-457-0820 (international); conference ID 9057897
- Webcast replay will be available on the Seattle Genetics
website at www.seattlegenetics.com in the Investors section
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes
transformative therapies targeting cancer to make a meaningful
difference in people’s lives. ADCETRIS® (brentuximab vedotin)
utilizes the company’s industry-leading antibody-drug conjugate
(ADC) technology and is currently approved for the treatment of
multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company
has established a pipeline of novel targeted therapies at various
stages of clinical testing, including three in ongoing pivotal
trials for solid tumors. Enfortumab vedotin for metastatic
urothelial cancer and tisotumab vedotin for metastatic cervical
cancer utilize our proprietary ADC technology. Tucatinib, a small
molecule tyrosine kinase inhibitor, is in a pivotal trial for
HER2-positive metastatic breast cancer. In addition, we are
leveraging our expertise in empowered antibodies to build a
portfolio of proprietary immuno-oncology agents in clinical trials
targeting hematologic malignancies and solid tumors. The company is
headquartered in Bothell, Washington, and has a European office in
Switzerland. For more information on our robust pipeline, visit
www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191008005271/en/
Investors Peggy Pinkston (425) 527-4160
ppinkston@seagen.com
Media Monique Greer (425) 527-4641 mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024